uracil has been researched along with Carcinoma, Anaplastic in 39 studies
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder
| Excerpt | Relevance | Reference |
|---|---|---|
| "Trifluridine/tipiracil (FTD/TPI) shows promising antitumor activity in heavily pretreated patients with advanced biliary tract carcinoma, including patients with 5-fluorouracil refractory tumors." | 9.34 | Phase II Trial of Trifluridine/Tipiracil in Patients with Advanced, Refractory Biliary Tract Carcinoma. ( Ahn, DH; Alberts, SR; Bekaii-Saab, TS; Borad, MJ; Chakrabarti, S; Durgin, LM; Fruth, B; Hartgers, ML; Liu, MC; Mahipal, A; McWilliams, RR; Ou, FS; Walkes, RL; Wessling, J; Zemla, TJ, 2020) |
| "This is an open-label, nonrandomized phase I trial to determine the safety and maximum tolerated dose of irinotecan with a fixed dose of UFT plus oral leucovorin in patients with advanced or metastatic colorectal cancer." | 9.09 | UFT/leucovorin plus weekly irinotecan in advanced or metastatic colorectal cancer. ( Hegewisch-Becker, S; Hossfeld, DK; Lipp, R; Schilling, G, 2000) |
| "Sixty eligible patients who had previously untreated, measurable, metastatic colorectal carcinoma were treated with oral eniluracil 50 mg on Days 1-7, 5-FU 20 mg/m(2) on Days 2-6, and LV 50 mg on Days 2-6." | 9.09 | Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma. ( Hollis, D; Mayer, RJ; Meropol, NJ; Niedzwiecki, D; Schilsky, RL, 2001) |
| "Fifty-two patients with advanced gastric carcinoma received epirubicin, cisplatin, and oral UFT plus leucovorin." | 9.09 | Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma. ( Hyun, JH; Jeen, YT; Kim, BS; Kim, CS; Kim, JS; Kim, YH; Mok, YJ; Shin, SW; Yoon, SY, 2001) |
| " In a previous study, the authors demonstrated that the combination of uracil and tegafur (UFT) with leucovorin (LV) was active and well tolerated in patients with advanced colorectal carcinoma (ACC)." | 7.69 | Uracil and tegafur modulated with leucovorin: an effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. Oncopaz Cooperative Group. ( Colmenarejo, A; de Castro, J; de la Gándara, I; Espinosa, E; Espinosa, J; Feliu, J; Fernández, Y; García Girón, C; González Barón, M; Jalón, JI, 1997) |
| "Effects of N-(6-aminohexyl)-1-naphthalenesulfonamide (W-5) and N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7) on antitumor activity of 1-(2-tetrahydrofuryl)-5-fluorouracil (ftorafur, FT) and a mixture of FT and uracil (UFT) were determined in nude mice bearing human ovarian carcinoma (KF cells)." | 7.67 | Adjuvant effects of calmodulin antagonists on antitumor activity of 1-(2-tetrahydrofuryl)-5-fluorouracil (ftorafur) and a mixture of ftorafur and uracil (UFT) in nude mice bearing human ovarian carcinomas. ( Iwano, I; Kikuchi, Y; Kita, T; Kizawa, I; Kuki, E; Miyauchi, M; Oomori, K, 1989) |
| "Trifluridine/tipiracil (FTD/TPI) shows promising antitumor activity in heavily pretreated patients with advanced biliary tract carcinoma, including patients with 5-fluorouracil refractory tumors." | 5.34 | Phase II Trial of Trifluridine/Tipiracil in Patients with Advanced, Refractory Biliary Tract Carcinoma. ( Ahn, DH; Alberts, SR; Bekaii-Saab, TS; Borad, MJ; Chakrabarti, S; Durgin, LM; Fruth, B; Hartgers, ML; Liu, MC; Mahipal, A; McWilliams, RR; Ou, FS; Walkes, RL; Wessling, J; Zemla, TJ, 2020) |
| " Diarrhea was the principal dose-limiting toxicity of oral 5-FU and eniluracil given on this chronic schedule." | 5.09 | Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil. ( Baker, SD; Diasio, RB; Donehower, RC; Grochow, LB; Hohneker, JA; Khor, SP; Lucas, VS; O'Reilly, S; Rowinsky, EK; Sartorius, SE; Spector, T, 2000) |
| "This is an open-label, nonrandomized phase I trial to determine the safety and maximum tolerated dose of irinotecan with a fixed dose of UFT plus oral leucovorin in patients with advanced or metastatic colorectal cancer." | 5.09 | UFT/leucovorin plus weekly irinotecan in advanced or metastatic colorectal cancer. ( Hegewisch-Becker, S; Hossfeld, DK; Lipp, R; Schilling, G, 2000) |
| "Sixty eligible patients who had previously untreated, measurable, metastatic colorectal carcinoma were treated with oral eniluracil 50 mg on Days 1-7, 5-FU 20 mg/m(2) on Days 2-6, and LV 50 mg on Days 2-6." | 5.09 | Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma. ( Hollis, D; Mayer, RJ; Meropol, NJ; Niedzwiecki, D; Schilsky, RL, 2001) |
| "Fifty-two patients with advanced gastric carcinoma received epirubicin, cisplatin, and oral UFT plus leucovorin." | 5.09 | Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma. ( Hyun, JH; Jeen, YT; Kim, BS; Kim, CS; Kim, JS; Kim, YH; Mok, YJ; Shin, SW; Yoon, SY, 2001) |
| "The activity and toxicity of UFT (Tegafur and Uracil) in a 4:1 molar concentration, plus leucovorin (LV), were evaluated in the treatment of 45 patients with advanced, bidimensionally measurable metastatic colorectal carcinoma." | 5.08 | Phase II study of UFT plus leucovorin in colorectal cancer. ( Pazdur, R, 1997) |
| "Thirty-nine patients with locally advanced or metastatic gastric carcinoma received oral UFT (tegafur and uracil) plus leucovorin." | 5.08 | A phase II trial. Oral UFT and leucovorin in patients with advanced gastric carcinoma. ( Kim, BS; Kim, JG; Kim, JS; Kim, YH; Park, YT; Shin, SW, 1997) |
| " Using a murine dorsal air sac (DAS) assay, we have previously shown that UFT and its metabolites, gamma-hydroxybutyric acid (GHB) and 5-fluorouracil (5-FU), inhibited the angiogenesis induced by murine renal cell carcinoma." | 3.71 | gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor. ( Aoyagi, K; Basaki, Y; Chikahisa, L; Hashimoto, A; Miyadera, K; Okabe, S; Wierzba, K; Yamada, Y; Yonekura, K, 2001) |
| " In a previous study, the authors demonstrated that the combination of uracil and tegafur (UFT) with leucovorin (LV) was active and well tolerated in patients with advanced colorectal carcinoma (ACC)." | 3.69 | Uracil and tegafur modulated with leucovorin: an effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. Oncopaz Cooperative Group. ( Colmenarejo, A; de Castro, J; de la Gándara, I; Espinosa, E; Espinosa, J; Feliu, J; Fernández, Y; García Girón, C; González Barón, M; Jalón, JI, 1997) |
| "Effects of N-(6-aminohexyl)-1-naphthalenesulfonamide (W-5) and N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7) on antitumor activity of 1-(2-tetrahydrofuryl)-5-fluorouracil (ftorafur, FT) and a mixture of FT and uracil (UFT) were determined in nude mice bearing human ovarian carcinoma (KF cells)." | 3.67 | Adjuvant effects of calmodulin antagonists on antitumor activity of 1-(2-tetrahydrofuryl)-5-fluorouracil (ftorafur) and a mixture of ftorafur and uracil (UFT) in nude mice bearing human ovarian carcinomas. ( Iwano, I; Kikuchi, Y; Kita, T; Kizawa, I; Kuki, E; Miyauchi, M; Oomori, K, 1989) |
| " GEM was administrated at a dosage of 1 g/m(2) intravenously weekly 3 of 4 weeks and UFT at a dosage of 200 mg/day orally continuously." | 2.73 | A randomized phase II trial of adjuvant chemotherapy with uracil/tegafur and gemcitabine versus gemcitabine alone in patients with resected pancreatic cancer. ( Furukawa, K; Ito, H; Kato, A; Kimura, F; Miyazaki, M; Nozawa, S; Otsuka, M; Shimizu, H; Togawa, A; Yoshidome, H; Yoshitomi, H, 2008) |
| "No effective treatment for advanced esophageal cancer extending to adjacent organs or associated with distant metastasis is known." | 2.71 | Concurrent chemoradiotherapy for locally advanced and metastatic esophageal cancer: longterm results of a phase II study of UFT/CDDP with radiotherapy. ( Horiuchi, Y; Indo, T; Iwase, H; Iyo, T; Kaida, S; Kato, E; Kusugami, K; Nakamura, M; Nakarai, K; Shimada, M, 2003) |
| "Distant metastases rate (DMR) was significantly reduced with CRT (14." | 2.71 | Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study. ( Au, GK; Chan, RT; Cheng, AC; Choy, DD; Chua, DT; Kwok, CC; Kwong, DL; Kwong, PW; Law, MW; Sham, JS; Wan, KY; Wu, PM; Yau, CC, 2004) |
| "We report a case of anaplastic carcinoma of the thyroid administered peroral fluorinated pyrimidine, providing longterm survival during three years." | 1.35 | [A case of anaplastic carcinoma of thyroid administered peroral fluorinated pyrimidine for long-term survival during three years]. ( Kira, M; Takizawa, H; Tangoku, A; Toba, H; Yamai, H; Yoshida, T, 2009) |
| " Pharmacokinetic modulating chemotherapy (PMC), a combination of infused 5-fluorouracil and oral uracil-tegafur, has been proven to be highly effective for the treatment of colorectal carcinoma." | 1.32 | Modified pharmacokinetic modulating chemotherapy using 5-fluorouracil, UFT, and taxotere (docetaxel) for advanced gastric cancer. ( Kobayashi, M; Konishi, N; Kusunoki, M; Mohri, Y; Ohmori, Y; Tanaka, K; Tonouchi, H, 2003) |
| " Rats were dosed p." | 1.29 | 5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil. ( Baccanari, DP; Cao, S; Davis, ST; Joyner, SS; Rustum, YM; Spector, T, 1995) |
| "A 66-year-old woman with left breast cancer (medullary carcinoma; T1cN1M0; Stage II A) was treated with breast conserving therapy combined with lumpectomy, radiotherapy, chemotherapy and endocrine therapy beginning in March, 1990." | 1.28 | [A case report of bone metastasis diagnosed by MRI and effectively treated with UFT after breast conserving therapy for breast cancer]. ( Hamada, N; Inomata, T; Nishioka, A; Ogawa, Y; Ogoshi, S; Sawada, A; Tanaka, Y; Terashima, M, 1992) |
| "Contrary to bladder tumors, the incidence of renal pelvic and ureteric tumors was increased by this regimen." | 1.27 | Production of urinary tract tumors by co-administration of uracil and N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide in F344 rats. ( Croft, WA; Hayashida, S; Kamiryo, Y; Wang, CY, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (38.46) | 18.7374 |
| 1990's | 10 (25.64) | 18.2507 |
| 2000's | 12 (30.77) | 29.6817 |
| 2010's | 1 (2.56) | 24.3611 |
| 2020's | 1 (2.56) | 2.80 |
| Authors | Studies |
|---|---|
| Chakrabarti, S | 1 |
| Zemla, TJ | 1 |
| Ahn, DH | 1 |
| Ou, FS | 1 |
| Fruth, B | 1 |
| Borad, MJ | 1 |
| Hartgers, ML | 1 |
| Wessling, J | 1 |
| Walkes, RL | 1 |
| Alberts, SR | 1 |
| McWilliams, RR | 1 |
| Liu, MC | 1 |
| Durgin, LM | 1 |
| Bekaii-Saab, TS | 1 |
| Mahipal, A | 1 |
| Sunaga, T | 1 |
| Suzuki, S | 1 |
| Kogo, M | 1 |
| Kurihara, T | 1 |
| Kaji, S | 1 |
| Koike, N | 1 |
| Harada, N | 1 |
| Suzuki, M | 2 |
| Kiuchi, Y | 1 |
| Yoshitomi, H | 1 |
| Togawa, A | 1 |
| Kimura, F | 1 |
| Ito, H | 1 |
| Shimizu, H | 1 |
| Yoshidome, H | 1 |
| Otsuka, M | 1 |
| Kato, A | 1 |
| Nozawa, S | 1 |
| Furukawa, K | 1 |
| Miyazaki, M | 1 |
| Yamai, H | 1 |
| Yoshida, T | 1 |
| Toba, H | 1 |
| Kira, M | 1 |
| Takizawa, H | 1 |
| Tangoku, A | 1 |
| HEIDELBERGER, C | 1 |
| LEIBMAN, KC | 1 |
| HARBERS, E | 1 |
| BHARGAVA, PM | 1 |
| EVANS, JS | 1 |
| MENGEL, GD | 1 |
| KHO, MC | 1 |
| PARSONNET, V | 1 |
| DEREN, TL | 1 |
| WILSON, WL | 1 |
| SHARP, GS | 1 |
| BENEFIEL, WW | 1 |
| OKADA, TA | 1 |
| ROBERTS, E | 1 |
| WOODRUFF, MW | 1 |
| MURPHY, WT | 2 |
| HODSON, JM | 1 |
| LANGEN, P | 1 |
| VENKER, P | 1 |
| ZIMMERMAN, M | 1 |
| SEIDENBERG, J | 1 |
| HOSLEY, HF | 1 |
| MARANGOUDAKIS, S | 1 |
| ROSS, CA | 1 |
| HOLLAND, JF | 1 |
| SCHELL, HW | 1 |
| CRESSY, NL | 1 |
| Iwase, H | 1 |
| Shimada, M | 1 |
| Nakamura, M | 1 |
| Nakarai, K | 1 |
| Iyo, T | 1 |
| Kaida, S | 1 |
| Indo, T | 1 |
| Kato, E | 1 |
| Horiuchi, Y | 1 |
| Kusugami, K | 1 |
| Tanaka, K | 1 |
| Konishi, N | 1 |
| Ohmori, Y | 1 |
| Kobayashi, M | 1 |
| Mohri, Y | 1 |
| Tonouchi, H | 1 |
| Kusunoki, M | 1 |
| Takeuchi, S | 1 |
| Nakayama, A | 1 |
| Ishida, S | 1 |
| Katsuragi, A | 1 |
| Adachi, M | 1 |
| Kwong, DL | 1 |
| Sham, JS | 1 |
| Au, GK | 1 |
| Chua, DT | 1 |
| Kwong, PW | 1 |
| Cheng, AC | 1 |
| Wu, PM | 1 |
| Law, MW | 1 |
| Kwok, CC | 1 |
| Yau, CC | 1 |
| Wan, KY | 1 |
| Chan, RT | 1 |
| Choy, DD | 1 |
| Cao, S | 1 |
| Baccanari, DP | 1 |
| Joyner, SS | 1 |
| Davis, ST | 1 |
| Rustum, YM | 1 |
| Spector, T | 2 |
| Pazdur, R | 2 |
| Feliu, J | 1 |
| González Barón, M | 1 |
| Espinosa, E | 1 |
| García Girón, C | 1 |
| de la Gándara, I | 1 |
| Espinosa, J | 1 |
| Colmenarejo, A | 1 |
| Jalón, JI | 1 |
| Fernández, Y | 1 |
| de Castro, J | 1 |
| Kim, YH | 2 |
| Shin, SW | 2 |
| Kim, BS | 2 |
| Park, YT | 1 |
| Kim, JG | 1 |
| Kim, JS | 2 |
| Ogawa, K | 1 |
| Uzvolgyi, E | 1 |
| St John, MK | 1 |
| de Oliveira, ML | 1 |
| Arnold, L | 1 |
| Cohen, SM | 1 |
| Lassere, Y | 1 |
| Diaz-Canton, E | 1 |
| Ho, DH | 1 |
| Oki, E | 1 |
| Sakaguchi, Y | 1 |
| Toh, Y | 1 |
| Oda, S | 1 |
| Maehara, Y | 1 |
| Yamamoto, N | 1 |
| Sugimachi, K | 1 |
| Rubiales, AS | 1 |
| del Valle, ML | 1 |
| Baker, SD | 1 |
| Diasio, RB | 1 |
| O'Reilly, S | 1 |
| Lucas, VS | 1 |
| Khor, SP | 1 |
| Sartorius, SE | 1 |
| Donehower, RC | 1 |
| Grochow, LB | 1 |
| Hohneker, JA | 1 |
| Rowinsky, EK | 1 |
| Schilling, G | 1 |
| Lipp, R | 1 |
| Hegewisch-Becker, S | 1 |
| Hossfeld, DK | 1 |
| Meropol, NJ | 1 |
| Niedzwiecki, D | 1 |
| Hollis, D | 1 |
| Schilsky, RL | 1 |
| Mayer, RJ | 1 |
| Jeen, YT | 1 |
| Yoon, SY | 1 |
| Mok, YJ | 1 |
| Kim, CS | 1 |
| Hyun, JH | 1 |
| Reimer, P | 1 |
| Rückle-Lanz, H | 1 |
| Basaki, Y | 1 |
| Chikahisa, L | 1 |
| Aoyagi, K | 1 |
| Miyadera, K | 1 |
| Yonekura, K | 1 |
| Hashimoto, A | 1 |
| Okabe, S | 1 |
| Wierzba, K | 1 |
| Yamada, Y | 1 |
| Nishioka, A | 1 |
| Ogawa, Y | 1 |
| Hamada, N | 1 |
| Terashima, M | 1 |
| Sawada, A | 1 |
| Inomata, T | 1 |
| Tanaka, Y | 1 |
| Ogoshi, S | 1 |
| Moreira, LF | 1 |
| Iwagaki, H | 1 |
| Hizuta, A | 1 |
| Sakagami, K | 1 |
| Mimura, H | 1 |
| Orita, K | 1 |
| Kikuchi, Y | 1 |
| Oomori, K | 1 |
| Iwano, I | 1 |
| Kizawa, I | 1 |
| Miyauchi, M | 1 |
| Kita, T | 1 |
| Kuki, E | 1 |
| Hanaue, H | 1 |
| Kurosawa, T | 1 |
| Kitano, Y | 1 |
| Miyakawa, S | 1 |
| Nemoto, A | 1 |
| Yamoto, H | 1 |
| Asagoe, T | 1 |
| Shikata, J | 1 |
| Wang, CY | 1 |
| Kamiryo, Y | 1 |
| Hayashida, S | 1 |
| Croft, WA | 1 |
| Richards, EG | 1 |
1 review available for uracil and Carcinoma, Anaplastic
| Article | Year |
|---|---|
[New therapeutic options in chemotherapy of advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Clinical Tria | 2001 |
11 trials available for uracil and Carcinoma, Anaplastic
| Article | Year |
|---|---|
Phase II Trial of Trifluridine/Tipiracil in Patients with Advanced, Refractory Biliary Tract Carcinoma.
Topics: Biliary Tract; Carcinoma; Humans; Pyrrolidines; Thymine; Trifluridine; Uracil | 2020 |
A randomized phase II trial of adjuvant chemotherapy with uracil/tegafur and gemcitabine versus gemcitabine alone in patients with resected pancreatic cancer.
Topics: Adenocarcinoma, Papillary; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; C | 2008 |
Concurrent chemoradiotherapy for locally advanced and metastatic esophageal cancer: longterm results of a phase II study of UFT/CDDP with radiotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combi | 2003 |
Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcin | 2004 |
Phase II study of UFT plus leucovorin in colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal Neoplasms; Drug Combinations; | 1997 |
A phase II trial. Oral UFT and leucovorin in patients with advanced gastric carcinoma.
Topics: Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Diarrhea; Drug Co | 1997 |
Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 28-day schedule.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Coloni | 1998 |
Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antimetabolites, Antineo | 2000 |
UFT/leucovorin plus weekly irinotecan in advanced or metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2000 |
Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplasti | 2001 |
Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cispla | 2001 |
27 other studies available for uracil and Carcinoma, Anaplastic
| Article | Year |
|---|---|
The association between neutropenia and prognosis in stage III colorectal cancer patients receiving adjuvant chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemother | 2014 |
[A case of anaplastic carcinoma of thyroid administered peroral fluorinated pyrimidine for long-term survival during three years].
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Pr | 2009 |
The comparative utilization of uracil-2-C14 by liver, intestinal mucosa, and Flexner-Jobling carcinoma in the rat.
Topics: Animals; Carcinoma; Intestinal Mucosa; Liver; Neoplasms; Rats; Uracil | 1957 |
Antitumor activity of 5-bis(2-chloroethyl) amino uracil against sarcoma 180 and Ehrlich carcinoma.
Topics: Animals; Carcinoma; Mechlorethamine; Nitrogen Mustard Compounds; Sarcoma 180; Uracil | 1958 |
Observations on the use of 5-fluorouracil in metastatic carcinoma of the breast.
Topics: Antineoplastic Agents; Breast; Breast Neoplasms; Carcinoma; Fluorouracil; Humans; Uracil | 1961 |
Use of 5-fluorouracil in treatment of bladder carcinomas.
Topics: Antineoplastic Agents; Carcinoma; Fluorouracil; Uracil; Urinary Bladder Neoplasms | 1960 |
5-Fluorouracil in the treatment of inoperable carcinoma of the colon and rectum.
Topics: Antineoplastic Agents; Carcinoma; Colonic Neoplasms; Fluorouracil; Humans; Rectal Neoplasms; Rectum; | 1962 |
Antimitotic action of 5-(2'-bromo-acetamido)-uracil on the Ehrlich ascites tumor.
Topics: Animals; Antimitotic Agents; Antineoplastic Agents; Carcinoma; Carcinoma, Ehrlich Tumor; Fluorouraci | 1962 |
The use of combination 5-fluorouracil and supervoltage irradiation therapy in advanced carcinoma of the urinary bladder--a preliminary report.
Topics: Carcinoma; Cell- and Tissue-Based Therapy; Fluorouracil; Humans; Multiple Myeloma; Plasma Cells; Ura | 1962 |
[ON THE INCORPORATION OF BROMOURACIL INTO THE DESOXYRIBONUCLEIC ACID OF TUMOR-BEARING MICE BY ADMINISTRATION OF BROMOURACIL AND DESOXYGUANOSINE].
Topics: Animals; Bromouracil; Carcinoma; Carcinoma, Ehrlich Tumor; DNA; DNA, Neoplasm; Mice; Nucleosides; Re | 1963 |
DEOXYRIBOSYL TRANSFER. I. THYMIDINE PHOSPHORYLASE AND NUCLEOSIDE DEOXYRIBOSYLTRANSFERASE IN NORMAL AND MALIGNANT TISSUES.
Topics: Animals; Breast Neoplasms; Carcinoma; Carcinoma, Ehrlich Tumor; Cattle; Colonic Neoplasms; Cricetina | 1964 |
Combined radiation-chemotherapy for bronchogenic carcinoma--pilot study.
Topics: Antineoplastic Agents; Carcinoma; Carcinoma, Bronchogenic; Dactinomycin; Folic Acid Antagonists; Hum | 1962 |
Clinical studies with 5-fluorouracil in 47 patients.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Carcinoma; Carcinoma, Squamous Cell; Fluorourac | 1962 |
Modified pharmacokinetic modulating chemotherapy using 5-fluorouracil, UFT, and taxotere (docetaxel) for advanced gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Docetaxel; Fluorouracil; Humans; Infusion | 2003 |
[A case of huge submandibular malignant tumor treated successfully with UFT chemotherapy].
Topics: Administration, Oral; Aged; Antineoplastic Agents; Carcinoma; Combined Modality Therapy; Drug Admini | 2004 |
5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil.
Topics: Animals; Carcinoma; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Drug Synergism; Enzyme | 1995 |
Uracil and tegafur modulated with leucovorin: an effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. Oncopaz Cooperative Group.
Topics: Administration, Oral; Aged; Aged, 80 and over; Ambulatory Care; Antidotes; Antimetabolites, Antineop | 1997 |
Frequent p53 mutations and occasional loss of chromosome 4 in invasive bladder carcinoma induced by N-butyl-N-(4-hydroxybutyl)nitrosamine in B6D2F1 mice.
Topics: Animals; Butylhydroxybutylnitrosamine; Carcinogens; Carcinoma; Chromosome Deletion; Humans; Male; Mi | 1998 |
Induction of apoptosis in human tumour xenografts after oral administration of uracil and tegafur to nude mice bearing tumours.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma; Cell Division; Colonic Neoplasms; Ga | 1998 |
Protracted treatment with tegafur and low dose oral leucovorin in patients with advanced colorectal carcinoma.
Topics: Administration, Oral; Antidotes; Antimetabolites, Antineoplastic; Carcinoma; Clinical Trials as Topi | 1999 |
gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma; Carc | 2001 |
[A case report of bone metastasis diagnosed by MRI and effectively treated with UFT after breast conserving therapy for breast cancer].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast N | 1992 |
Can cytokines prolong survival in ampullary neuroendocrine carcinomas?
Topics: Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined Modality Thera | 1992 |
Adjuvant effects of calmodulin antagonists on antitumor activity of 1-(2-tetrahydrofuryl)-5-fluorouracil (ftorafur) and a mixture of ftorafur and uracil (UFT) in nude mice bearing human ovarian carcinomas.
Topics: Animals; Calmodulin; Carcinoma; Drug Combinations; Drug Synergism; Female; Fluorouracil; Mice; Mice, | 1989 |
[Drug distribution to lymph and blood in adjuvant chemotherapy with combined preparation of 1-(2-tetrahydrofuryl)-5-fluorouracil and uracil after surgery in gastric cancer patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined Modality Therapy; Humans; Lymph; | 1987 |
Production of urinary tract tumors by co-administration of uracil and N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide in F344 rats.
Topics: Animals; Body Weight; Carcinoma; Cocarcinogenesis; FANFT; Female; Hyperplasia; Kidney Pelvis; Rats; | 1987 |
5S RNA. An analysis of possible base pairing schemes.
Topics: Adenine; Carcinoma; Cell Line; Chemical Phenomena; Chemistry; Computers; Cytosine; Escherichia coli; | 1969 |